Albany, NY -- (SBWIRE) -- 10/29/2018 -- DelveInsight has announced the addition of the "Primary Biliary Cholangitis (PBC)-Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Primary Biliary Cholangitis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Primary Biliary Cholangitis from 2018 to 2027 segmented by seven major markets.

Request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Primary-Biliary-Cholangitis-(PBC)---Market-Insights,-Epidemiology-and-Market-Forecast-2027

Primary Biliary Cholangitis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age. It leads to inflammation and scarring of the small bile ducts. If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure. PBC is divided into four stages with stage 1 being early disease, where this is no significant scarring, to stage 4, which is defined by cirrhosis. The most common symptom of PBC is fatigue. When PBC is very severe, it can lead to yellow discolouration of the skin (jaundice). PBC is common among women of middle age worldwide. The disease ratio among female to male is 9:1.

In 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons. In the UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of the cases were reported in women. Epidemiological studies have also revealed the prevalence of PBC to be around 27–54 per million cases in Japan. As per one study conducted, approximately 7–11% of PBC patients are males.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. CymaBay Therapeutics
2. Fast Forward Pharmaceuticals
3. Arena Pharmaceuticals
4. Enanta Pharmaceuticals
5. Genkyotex)
And many others

Drugs covered

1. Seladelpar
2. FFP104
3. Etrasimod
4. EDP-305
5. GKT831
And many others

Report Scope

The report covers the descriptive overview of Primary Biliary Cholangitis (PBC) explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides insight into the epidemiology of PBC and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Primary Biliary Cholangitis (PBC) market size covering the drug outreach in 7MM. The report provides an understanding of the future competition in Primary Biliary Cholangitis (PBC) by reviewing the market drivers and barriers.